ArticleFEMS immunology and medical microbiology2008
Inhibition of Candida albicans adhesion by recombinant human antibody single-chain variable fragment specific for Als3p.
Article in FEMS immunology and medical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Targeting Als3 adhesin of clinically relevant Candida species using natural carotenoids: an in-silico study.Molecular diversity · 2026Article
- Cleavage of cell junction proteins as a host invasion strategy in leptospirosis.Applied microbiology and biotechnology · 2024Review
- The prophylactic effects of monoclonal antibodies targeting the cell wall Pmt4 protein epitopes ofFrontiers in microbiology · 2022Article
- Fungal Cell Wall Proteins and Signaling Pathways Form a Cytoprotective Network to Combat Stresses.Journal of fungi (Basel, Switzerland) · 2021Review
- Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.Frontiers in cellular and infection microbiology · 2021Review
- Review
- Current trends to control fungal pathogens: exploiting our knowledge in the host-pathogen interaction.Infection and drug resistance · 2018Review
- Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Proteomics. Clinical applications · 2016Review
- Neonatal Candidiasis: New Insights into an Old Problem at a Unique Host-Pathogen Interface.Current fungal infection reports · 2015Article
- Emerging drugs and vaccines for candidemia.Mycoses · 2014Review
- In vitro models of hematogenously disseminated candidiasis.Virulence · 2014Article
- Extracellular enolase of Candida albicans is involved in colonization of mammalian intestinal epithelium.Frontiers in cellular and infection microbiology · 2014Article
- Candida virulence properties and adverse clinical outcomes in neonatal candidiasis.The Journal of pediatrics · 2012Article
- A murine model for disseminated candidiasis in neonates.Pediatric research · 2011Article
- Candida albicans Als3, a multifunctional adhesin and invasin.Eukaryotic cell · 2011Review
- Deletion of Candida albicans SPT6 is not lethal but results in defective hyphal growth.Fungal genetics and biology : FG & B · 2010Article
- Monoclonal antibodies specific for Candida albicans Als3 that immunolabel fungal cells in vitro and in vivo and block adhesion to host surfaces.Journal of microbiological methods · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
The Candida albicans adhesin, Als3p, was identified as a potential cognate antigen for previously described human antibody fragments [single-chain variable fragment (scFv)] based on similarity of the binding pattern of the scFv to the distribution of this protein on the hyphal surface. Although all scFv bound avidly to wild type, scFv3 showed no detectable binding via immunofluorescence assay to strain 1843, containing a homozygous deletion of ALS3. Binding to the ALS3 reintegrant strain, 2322, was preserved, and scFv3 also bound to Saccharomyces cerevisiae expressing ALS3. Other scFv retained binding to 1843, but with a markedly altered pattern. To determine if scFv3 could interfere with Als3p function, adhesion assays were conducted using human epithelial or endothelial cells as target. Treatment of wild-type C. albicans with scFv3 reduced adhesion of the fungus to both cell types to levels comparable to the als3Delta/als3Delta mutant. These experiments confirm that phage display is a viable method to isolate human scFv specific to an antigen implicated in C. albicans virulence, and that the scFv interfere with adhesion to human cells. The altered pattern of immunostaining with other scFv that retain binding to the als3Delta/als3Delta mutant suggest that Als3p may also have a role in structural organization of the C. albicans cell surface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.